No Data
shandong pharmaceutical glass (600529.SH): The landing of the tenth batch of centralized procurement is expected to bring bullish to the company's boron silicon products.
Gelonghui November 7th, Shandong Pharmaceutical Glass (600529.SH) stated on the investor interaction platform that the landing of the tenth batch of centralized procurement is expected to bring bullish effects to the company's borosilicate products, but it is not easy to determine the specific impact. Here, a reminder is given that "the stock market is risky and investment needs to be cautious".
Shandong pharmaceutical glass: October sales performance better than Q3 average level, current overall costs remain relatively stable | Direct hit earnings conference
①Regarding the situation in Q4, Zhang Jun, the General Manager of shandong pharmaceutical glass, stated that the declining business in Q3 has shown some improvement. According to the current situation, it is expected that Q4 will be better than Q3; ②In terms of costs, while the price of the main raw material caustic soda has decreased, energy prices have risen, resulting in overall costs remaining stable.
shandong pharmaceutical glass (600529.SH): Currently, the company is operating at full capacity.
Gelonghui reported on November 1st that shandong pharmaceutical glass (600529.SH) stated on the investor interaction platform that 1. currently the company is operating at full capacity; 2. the main reason for the quarter-on-quarter revenue decline in the third quarter of 2024 is that the revenue of the trading subsidiary decreased and the sales of some products decreased slightly due to the maintenance of the pharmaceutical factory, among other reasons; 3. currently, all types of products of the company have stable prices.
Shandong Pharmaceutical Glass (600529.SH): Currently no merger and reorganization plans.
GLEE11 reported on November 1st that shandong pharmaceutical glass (600529.SH) stated on the investor interaction platform that the company currently has no plans for merger and reorganization.
Shandong Pharmaceutical Glass Co.Ltd Just Missed Revenue By 12%: Here's What Analysts Think Will Happen Next
Shandong Pharmaceutical Glass: Report of Shandong Pharmaceutical Glass Co., Ltd. for the third quarter of 2024
No Data
No Data